News | February 12, 2015

New Bioresorbable Stent Uses Technology to Appear on Angiographic X-ray

New stent created with Rutgers technology in now in clinical trials

Fantom, Reva Medical, Rutgers, bioresorbable stents

Image courtesy of Reva Medical Inc.

February 12, 2015 — A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University of New Jersey, has been implanted in patients for the first time.

The device, called Fantom, is a drug-eluting stent being developed by Reva Medical Inc. of San Diego. The stent is made from a unique formulation from a tyrosine-based polymer family invented by Joachim Kohn, Rutgers Board of Governors professor of chemistry. The company signed the initial licensing agreement with Rutgers in 2004 for the polymer family.

The polymer is a major step forward because the stent made from the material is fully visible using X-ray, which is extremely useful to interventional cardiologists when they are implanting the device. The polymer also is fully bioresorbable, meaning that it dissolves completely over time, which is an advantage particularly for younger patients.

The first Fantom implants were done at Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil.

“This is a major step forward toward introducing a valuable new therapeutic tool that has the potential to help many patients worldwide,” Kohn said.

For more information:

Related Content

Videos | Stents Bioresorbable | August 06, 2018
Patrick Serruys, M.D., Ph.D., Imperial College London, explains where development of bioresorbable scaffolds stands i
Amaranth's Fortitute bioresorbable stent scaffold. The company is developing smaller strut BRS.  Data presented at EuroPCR 2018
Feature | Stents Bioresorbable | June 19, 2018
June 19, 2018 – Amaranth Medical offered new details about its 85-micron Defiance bioresorbable scaffold (BRS) recent
Videos | Stents Bioresorbable | November 07, 2017
A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-Presbyteri
Thirty-Day ABSORB IV Results Demonstrate Improvements Still Needed in Bioresorbable Stents
News | Stents Bioresorbable | October 31, 2017
Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS)...
Amaranth Medical to Share Bioresorbable Scaffold Data at TCT
News | Stents Bioresorbable | October 25, 2017
Amaranth Medical will provide an update at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, Oct. 29-...
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable | September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Videos | Stents Bioresorbable | March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
BVS, Absorb stent, bioresorbable scaffold, ABSORB III data, ABSORB III results
Feature | Stents Bioresorbable | March 21, 2017 | Dave Fornell
March 21, 2017 — In the late-breaking ABSORB III Trial two year results presented at the American College of Cardiolo
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable | January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Overlay Init